Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clay E S Comstock

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Endocrine-Related Cancer|July 3, 2013
IGF2 revs the steroidogenesis engineClay E S Comstock, Karen E Knudsen
Cell Cycle (Georgetown, Tex.)|June 15, 2007
The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeuticsClay E S Comstock, Karen E Knudsen
Endocrinology|October 1, 2005
LS14: a novel human adipocyte cell line that produces prolactinEric R Hugo, Terry D Brandebourg, Clay E S Comstock, et al.
Cancer Research|July 10, 2007
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cellsAnkur Sharma, Clay E S Comstock, Erik S Knudsen, et al.
Cancer Research|May 13, 2010
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogeneNicholas A Olshavsky, Clay E S Comstock, Matthew J Schiewer, et al.
Environmental Health Perspectives|November 17, 2007
Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation statusJanet K Hess-Wilson, Siobhan L Webb, Hannah K Daly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Aberrant BAF57 signaling facilitates prometastatic phenotypesSucharitha Balasubramaniam, Clay E S Comstock, Adam Ertel, et al.
Cancer Research|June 19, 2008
Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activityKevin A Link, Sucharitha Balasubramaniam, Ankur Sharma, et al.
The Journal of Biological Chemistry|January 8, 2011
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor functionClay E S Comstock, Michael A Augello, Matthew J Schiewer, et al.
Molecular Cancer Therapeutics|December 19, 2006
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancerYelena B Wetherill, Janet K Hess-Wilson, Clay E S Comstock, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Endocrine-Related Cancer|July 3, 2013
IGF2 revs the steroidogenesis engineClay E S Comstock, Karen E Knudsen
Cell Cycle (Georgetown, Tex.)|June 15, 2007
The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeuticsClay E S Comstock, Karen E Knudsen
Endocrinology|October 1, 2005
LS14: a novel human adipocyte cell line that produces prolactinEric R Hugo, Terry D Brandebourg, Clay E S Comstock, et al.
Cancer Research|July 10, 2007
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cellsAnkur Sharma, Clay E S Comstock, Erik S Knudsen, et al.
Cancer Research|May 13, 2010
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogeneNicholas A Olshavsky, Clay E S Comstock, Matthew J Schiewer, et al.
Environmental Health Perspectives|November 17, 2007
Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation statusJanet K Hess-Wilson, Siobhan L Webb, Hannah K Daly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Aberrant BAF57 signaling facilitates prometastatic phenotypesSucharitha Balasubramaniam, Clay E S Comstock, Adam Ertel, et al.
Cancer Research|June 19, 2008
Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activityKevin A Link, Sucharitha Balasubramaniam, Ankur Sharma, et al.
The Journal of Biological Chemistry|January 8, 2011
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor functionClay E S Comstock, Michael A Augello, Matthew J Schiewer, et al.
Molecular Cancer Therapeutics|December 19, 2006
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancerYelena B Wetherill, Janet K Hess-Wilson, Clay E S Comstock, et al.
Pageof 2